Actinium Pharmaceuticals (NYSE:ATNM) Announces Earnings Results

Actinium Pharmaceuticals (NYSE:ATNM) announced its earnings results on Monday. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.02, Yahoo Finance reports.

Actinium Pharmaceuticals Price Performance

Shares of NYSE:ATNM traded down $0.53 during trading on Wednesday, hitting $2.34. The company had a trading volume of 1,010,305 shares, compared to its average volume of 467,550. The firm has a market capitalization of $69.69 million, a price-to-earnings ratio of -1.54 and a beta of 0.20. Actinium Pharmaceuticals has a one year low of $1.33 and a one year high of $10.24.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ATNM. Stephens started coverage on shares of Actinium Pharmaceuticals in a research note on Tuesday, May 14th. They issued an “overweight” rating and a $25.00 price objective for the company. StockNews.com lowered Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday. HC Wainwright lowered their price target on Actinium Pharmaceuticals from $50.00 to $4.00 and set a “buy” rating on the stock in a report on Tuesday. Maxim Group lowered their target price on shares of Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $21.00 target price on shares of Actinium Pharmaceuticals in a research note on Tuesday, April 30th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, Actinium Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $13.77.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.